| Name | Title | Contact Details |
|---|---|---|
Poncho Meisenheimer |
Vice President Research And Development | Profile |
Cass Brouette |
Director of Project Management, R&D | Profile |
Mei Cong |
Research Director, Elite Access | Profile |
William Tarpley |
VP R&D | Profile |
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.
Molecular Insight Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marina Biotech is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedCure is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.